The AlphaLISA™ SureFire® Ultra™ Human STAT2 / IRF9 Complex assay is a sandwich immunoassay for quantitative detection of the STAT2 / IRF9 complex in cellular lysates using Alpha Technology.
| Feature | Specification |
|---|---|
| Application | Cell Signaling |
| Protocol Time | 2h at RT |
| Sample Volume | 10 µL |
The AlphaLISA™ SureFire® Ultra™ Human STAT2 / IRF9 Complex assay is a sandwich immunoassay for quantitative detection of the STAT2 / IRF9 complex in cellular lysates using Alpha Technology.
Loading...
The STAT2/IRF9 complex is a transcriptional regulatory assembly that mediates interferon signaling in contexts where STAT1 availability is limited or absent. Under canonical type I interferon signaling, STAT1, STAT2, and IRF9 assemble into the trimeric ISGF3 complex; however, STAT2 and IRF9 can also form a functional binary complex capable of binding interferon-stimulated response elements (ISREs) and driving expression of a subset of interferon-stimulated genes (ISGs). This STAT2/IRF9 complex provides a STAT1-independent mechanism for sustaining antiviral gene expression, which is particularly relevant in settings of STAT1 deficiency, viral antagonism of STAT1, or prolonged interferon stimulation where STAT1 levels are depleted. The STAT2/IRF9 complex has been shown to induce a distinct but overlapping ISG signature compared to ISGF3, with implications for the specificity and duration of antiviral responses. Detection of the STAT2/IRF9 complex, as distinct from individual STAT2 or IRF9 proteins or the full ISGF3 trimer, enables characterization of alternative interferon signaling states and is relevant to research in antiviral immunity, autoimmune disease, and viral immune evasion strategies.
The AlphaLISA SureFire Ultra Human STAT2 / IRF9 Complex Detection Kit is a sandwich immunoassay for the quantitative detection of STAT2 / IRF9 complex in cellular lysates, using Alpha Technology.
Formats:
AlphaLISA SureFire Ultra kits are compatible with:
AlphaLISA SureFire Ultra kits can be used for:
The AlphaLISA SureFire Ultra complex assay measures cellular protein-protein interactions (PPI) in a biological sample (e.g. cell lysate).
The assay uses two antibodies which recognize Protein 1 and Protein 2, respectively. AlphaLISA assays require two bead types: Acceptor and Donor Beads. Acceptor Beads are coated with a proprietary CaptSure™ agent to specifically immobilize the first assay antibody, labeled with a CaptSure tag. Donor Beads are coated with streptavidin to capture the second antibody, which is biotinylated. In the presence of the protein complex, the two antibodies bring the Donor and Acceptor Beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor Bead, allowing for the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of PPI present in the sample.
The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of complex AlphaLISA SureFire Ultra detection reagents. This protocol enables cell viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.
Detection of the protein complex with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining robust AlphaLISA SureFire Ultra quality.
A431 cells were seeded in a 96-well plate (30,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. Cells were treated with increasing concentrations of IFNβ for 24 hours.
After treatment, the cells were lysed with 50 µL or 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT2/IRF9 Complex and Cofilin Total levels were evaluated using AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 6,000 cells for Complex and 200 for Cofilin) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, IFNβ triggered a dose-dependent increase in STAT2/IRF9 Complex formation with no change to Cofilin levels.
THP-1 cells were seeded in a 96-well plate (200,000 cells/well) and treated with 10 ng/mL IFNβ or IFNγ for 24 hours in complete medium at 37°C, 5% CO2.
After treatment, the cells were washed with HBSS and then lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT2/IRF9 Complex levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate (approximately 20,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, treatment with type I or type II interferons increased STAT2/IRF9 Complex formation with no change to Cofilin Total (data not shown).
RPMI 8226 cells were seeded in a 96-well plate (200,000 cells/well) and treated with 10 ng/mL IFNβ for 24 hours in complete medium at 37°C, 5% CO2.
After treatment, the cells were washed with HBSS and then lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT2/IRF9 Complex levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate (approximately 20,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, treatment with IFNb increased STAT2/IRF9 Complex formation with no change to Cofilin Total (data not shown).
Cell lysate was prepared from A431 cells cultured to confluence in T175 flasks at 37°C, 5% CO2. Cells were treated with IFNβ for 24 hours and then lysed in 2 mL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm).
Lysate was serially diluted in Lysis Buffer and assayed for STAT2/IRF9 Complex levels using the AlphaLISA SureFire Ultra kit. For the detection step, 10 µL of lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at room temperature. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour in the dark. The plate was read on an Envision using standard AlphaLISA settings.
Approximate number of cells/datapoint is indicated on the graph. This assay can detect STAT2/IRF9 Complex in less than 3,000 cells. The dotted line represents assay background.
| Application |
Cell Signaling
|
|---|---|
| Automation Compatible |
Yes
|
| Brand |
AlphaLISA SureFire Ultra
|
| Detection Modality |
Alpha
|
| Product Group |
Kit
|
| Protocol Time |
2h at RT
|
| Sample Volume |
10 µL
|
| Shipping Conditions |
Shipped in Blue Ice
|
| Target |
STAT2 / IRF9
|
| Target Class |
Phosphoproteins
|
| Target Species |
Human
|
| Technology |
Alpha
|
| Therapeutic Area |
Autoimmunity
Virology
|
| Unit Size |
500 Assay Points
|
Are you looking for resources, click on the resource type to explore further.
Alpha technolgy enables the rapid and straightforward mesaure of virtually any target. This includes enzymes, receptor-ligand...
The definitive guide for setting up a successful AlphaLISA SureFire Ultra assay
Several biological processes are regulated by...
Discover Alpha SureFire® Ultra™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology...
This document includes detailed tables listing HTRF™, AlphaLISA™ SureFire® Ultra™, and Alpha SureFire® Ultra™ Multiplex assays...
Loading...
We are here to answer your questions.